Skip to content

Released Aug 8, 2024, before the open

10-Q filed Aug 8, 2024, 39 days after period end · 0001493152-24-030648

Q2 2024 · 10-Q
Revenue$89.57K— vs Q2 2023−98.8% vs Q1 2024
Net Income-$3.07MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.56N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$3,292,568N/M
Operating Cash Flowderived-$2,497,777N/M
Margins · derived
Operating margin-3676.2%
Net margin-3426.2%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$89.57K$0.00$500.00K—
Net Income-$3.07M-$3.55M-$2.63M-$6.81M
EPS Diluted-$0.56-$0.68-$0.61-$0.08

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR